Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
MMWR Morb Mortal Wkly Rep
; 71(8): 285-289, 2022 Feb 25.
Article
em En
| MEDLINE
| ID: mdl-35202353
ABSTRACT
On May 5, 2021, CDC's Tuberculosis Trials Consortium and the National Institutes of Health (NIH)-sponsored AIDS Clinical Trials Group (ACTG) published results from a randomized controlled trial indicating that a 4-month regimen containing rifapentine (RPT), moxifloxacin (MOX), isoniazid (INH), and pyrazinamide (PZA) was as effective as the standard 6-month regimen for tuberculosis (TB) treatment (1). On the basis of these findings, CDC recommends the 4-month regimen as a treatment option for U.S. patients aged ≥12 years with drug-susceptible pulmonary TB and provides implementation considerations for this treatment regimen.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirazinamida
/
Rifampina
/
Tuberculose Pulmonar
/
Moxifloxacina
/
Isoniazida
/
Antituberculosos
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
MMWR Morb Mortal Wkly Rep
Ano de publicação:
2022
Tipo de documento:
Article